Investment Rating - The report maintains an "Outperform" rating for the company [2][7]. Core Views - The maternity subsidy policy is expected to strengthen domestic demand for infant formula, leading to a recovery in sales [3][11]. - The company plans to invest 1.2 billion yuan in a nationwide birth subsidy program starting in April 2025, providing monthly subsidies of one can of infant formula for five months to new mothers [3][11]. - The new product Zhuo Rui has significantly outperformed older products, becoming the company's largest single product, with sales increasing over 60% year-on-year [4][12]. Financial Performance - The company achieved a revenue of 20.749 billion yuan in 2024, a year-on-year increase of 6.2%, with a net profit of 3.570 billion yuan, up 5.3% [4][12]. - The gross profit margin for 2024 was 66.3%, an increase of 1.5 percentage points year-on-year, attributed to reduced price promotions and lower raw material costs [5][13]. - The payout ratio for dividends was approximately 76% in 2024, with expectations for continued growth in absolute dividend amounts [6][14]. Earnings Forecast - Revenue projections for 2025-2027 are set at 22.11 billion, 23.75 billion, and 25.50 billion yuan, respectively, with corresponding net profits of 3.96 billion, 4.34 billion, and 4.65 billion yuan [7][15]. - The expected earnings per share (EPS) for 2025-2027 are 0.44, 0.48, and 0.51 yuan, respectively [7][15]. - The target price for the stock is set at HK$7.00, based on a price-to-earnings (P/E) ratio of 15 for 2025 [2][15].
中国飞鹤（06186）：生育补贴政策加力，奶粉需求有望复苏